American Heart Journal
Volume 147, Issue 1 , Pages 31-34 , January 2004

Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices

  • Jose E Exaire, MD

      Affiliations

    • Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Harold L Dauerman, MD

      Affiliations

    • Department of Cardiovascular Medicine, University of Vermont, Burlington, Vt, USA
    • ,
  • Eric J Topol, MD

      Affiliations

    • Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • James C Blankenship, MD

      Affiliations

    • Department of Cardiovascular Medicine, Geisinger Medical Center, Danville, Pa, USA
    • ,
  • Kathy Wolski

      Affiliations

    • Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Russell E Raymond, DO

      Affiliations

    • Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Eric A Cohen, MD

      Affiliations

    • Division of Cardiology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada
    • ,
  • David J Moliterno, MD

      Affiliations

    • Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Ky, USA
    • Corresponding Author InformationReprint requests: David J. Moliterno, MD, Chief, Cardiovascular Medicine, University of Kentucky, 900 S Limestone St, 317 Health Sciences Building, Lexington, KY 40536-0200, USA.
    • ,
  • the TARGET Investigators

Received 21 March 2003 ,Accepted 24 July 2003.

References 

  1. Aker UT, Kensey KR, Heuser RR, et al.  Immediate arterial hemostasis after cardiac catheterization (initial experience with a new puncture closure device). Cathet Cardiovasc Diagn. 1994;31:228–232
  2. Duffin DC, Muhlestein JB, Allisson SB, et al.  Femoral arterial puncture management after percutaneous coronary procedures (a comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices). J Invasive Cardiol. 2001;13:354–362
  3. Sesana M, Vaghetti M, Albiero R, et al.  Effectiveness and complications of vascular access closure devices after interventional procedures. J Invasive Cardiol. 2000;12:395–399
  4. Applegate RJ, Grabarczyk MA, Little WC, et al.  Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization. J Am Coll Cardiol. 2002;40:78–83
  5. Chamberlin JR, Lardi AB, McKeever LS, et al.  Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro). Catheter Cardiovasc Interv. 1999;47:143–147
  6. Assali AR, Sdringola S, Moustapha A, et al.  Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices. Catheter Cardiovasc Interv. 2003;58:1–5
  7. Baim DS, Knops WD, Hinohara T, et al.  Suture-mediated closure of the femoral access site after cardiac catheterization (results of the suture to ambulate and discharge (STAND I and STAND II) trials). Am J Cardiol. 2000;85:864–869
  8. Carey D, Martin JR, Moore CA, et al.  Complications of femoral artery closure devices. Catheter Cardiovasc Interv. 2001;52:3–7
  9. Dangas G, Mehran R, Kokolis S, et al.  Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol. 2001;38:638–641
  10. Cura FA, Kapadia SR, L'Allier PL, et al. Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. Am J Cardiol 86:780–2
  11. Moliterno DJ, Topol EJ. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement (rationale and design of the TARGET study). Am Heart J. 2000;140:722–726
  12. Topol EJ, Moliterno DJ, Herrmann HC, et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888–1894
  13. Bovill EG, Terrin ML, Stump DC, et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med. 1992;115:256–265
  14. Ellis SG, Elliot J, Horrigan M, et al.  Low-normal or excessive body mass index (newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention). Am J Cardiol. 1996;78:642–646
  15. Hitinder SG, Whitlow PL, Kip KE. The impact of body mass index on short- and long-term outcomes in patients undergoing coronary revascularization. J Am Coll Cardiol. 2002;39:834–840
  16. Hitinder SG, Brennan DM, Booth J, et al.  Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol. 2002;90:42–45
  17. Mandak JS, Blankenship JC, Gardner LH, et al.  Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. J Am Coll Cardiol. 1998;31:1518–1524
  18. Blankenship JC, Hellkamp AS, Aguirre FV, et al.  Vascular access site complications after percutaneous coronary interventions with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol. 1998;81:36–40
  19. Blankenship JC, Balog C, Sapp SK, et al.  Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. Cathet Cardiovasc Intervent. 2002;57:476–483

PII: S0002-8703(03)00605-7

doi: 10.1016/j.ahj.2003.07.019

American Heart Journal
Volume 147, Issue 1 , Pages 31-34 , January 2004

Article Tools